Please use this identifier to cite or link to this item: https://dspace.ctu.edu.vn/jspui/handle/123456789/54677
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVũ, Ngọc Doãn-
dc.contributor.authorTrần, Thị Ý Nhi-
dc.contributor.authorĐặng, Thị Tuyết Anh-
dc.contributor.authorHoàng, Thị Phương-
dc.contributor.authorNguyễn, Thị Hiển-
dc.contributor.authorĐinh, Thị Cúc-
dc.contributor.authorLê, Nhật Thùy Giang-
dc.contributor.authorNguyễn, Tuấn Anh-
dc.contributor.authorVũ, Thị Thu Hà-
dc.contributor.authorNguyễn, Văn Tuyến-
dc.date.accessioned2021-06-09T07:54:28Z-
dc.date.available2021-06-09T07:54:28Z-
dc.date.issued2018-
dc.identifier.issn0866-7861-
dc.identifier.urihttps://dspace.ctu.edu.vn/jspui/handle/123456789/54677-
dc.description.abstractViewing bortezomib as one of the first therapeuticals of antineoplastic drugs for patients with multiple myeloma and mantle lymphoma cells, the synthetic process of bortezomib was improved for simplicity better yield. The synthesized compounds were qulitatively confirmed by NMR and MS quantitatvely determined by HPLC. The synthesis achieved the yield of approximately 40%, the obtained bortezomib had the purity above 90%.vi_VN
dc.language.isovivi_VN
dc.relation.ispartofseriesTạp chí Dược học;Số 510 .- Tr.68-71-
dc.subjectBortezomibvi_VN
dc.subjectInhibitors drug Proteasome Ubiquitvi_VN
dc.titlePhương pháp cải tiến tổng hợp bortezomibvi_VN
dc.typeArticlevi_VN
Appears in Collections:Dược học

Files in This Item:
File Description SizeFormat 
_file_
  Restricted Access
2.94 MBAdobe PDF
Your IP: 18.225.54.147


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.